Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concerta in HIV-associated neurocognitive disorder
NCT01599975Phase 3Unknown
- Sponsor
- University of California, Los Angeles
- Start
- May 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate osmotic release oral system in HIV-associated neurocognitive disorder (HAND) (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Change in rate of reaction time at 10 weeks. Status: unknown.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
HIV-associated neurocognitive disorder (HAND)
Beyond the preview
Go deeper on NCT01599975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01599975.